Cargando…
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis
BACKGROUND: Bacterial vaginosis (BV), a prevalent infection in women of reproductive age, is associated with increased risk of upper genital tract and sexually transmitted infections, and complications in pregnancy. Currently approved treatments include metronidazole, which requires once or twice da...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463027/ https://www.ncbi.nlm.nih.gov/pubmed/26222750 http://dx.doi.org/10.1097/OLQ.0000000000000300 |
_version_ | 1782375758330593280 |
---|---|
author | Schwebke, Jane R. Marrazzo, Jeanne Beelen, Andrew P. Sobel, Jack D. |
author_facet | Schwebke, Jane R. Marrazzo, Jeanne Beelen, Andrew P. Sobel, Jack D. |
author_sort | Schwebke, Jane R. |
collection | PubMed |
description | BACKGROUND: Bacterial vaginosis (BV), a prevalent infection in women of reproductive age, is associated with increased risk of upper genital tract and sexually transmitted infections, and complications in pregnancy. Currently approved treatments include metronidazole, which requires once or twice daily intravaginal administration for 5 days or twice daily oral administration for 7 days. This phase 3 study determined the safety and efficacy of single-dose metronidazole vaginal gel (MVG) 1.3%. METHODS: In this double-blind, vehicle-controlled study, 651 women with clinical diagnosis of BV were randomized 1:1 to receive MVG 1.3% or vehicle vaginal gel. Primary efficacy measure was clinical cure (normal discharge, negative “whiff test,” and <20% clue cells) at day 21. Secondary measures included therapeutic cure (both clinical and bacteriological; day 21) and bacteriologic cure (Nugent score <4), clinical cure, and time to resolution of symptoms (day 7). RESULTS: A total of 487 participants were included in the primary analysis. Clinical and therapeutic cure rates (day 21) were higher in participants treated with MVG 1.3% compared with vehicle gel (37.2% vs. 26.6% [P = 0.010] and 16.8% vs. 7.2% [P = 0.001], respectively). Clinical and bacteriologic cure rates (day 7) were also higher in the MVG 1.3% group (46.0% vs. 20.0% [P < 0.001] and 32.7% vs. 6.3% [P < 0.001], respectively). The median time to resolution of symptoms was shorter in the MVG 1.3% (day 6) than vehicle group (not reached). No serious adverse events were reported, and incidence was similar across treatment groups. CONCLUSIONS: Single-dose MVG 1.3% was safe and superior to vehicle gel in producing cure among women with BV. |
format | Online Article Text |
id | pubmed-4463027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-44630272015-06-30 A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis Schwebke, Jane R. Marrazzo, Jeanne Beelen, Andrew P. Sobel, Jack D. Sex Transm Dis Original Study BACKGROUND: Bacterial vaginosis (BV), a prevalent infection in women of reproductive age, is associated with increased risk of upper genital tract and sexually transmitted infections, and complications in pregnancy. Currently approved treatments include metronidazole, which requires once or twice daily intravaginal administration for 5 days or twice daily oral administration for 7 days. This phase 3 study determined the safety and efficacy of single-dose metronidazole vaginal gel (MVG) 1.3%. METHODS: In this double-blind, vehicle-controlled study, 651 women with clinical diagnosis of BV were randomized 1:1 to receive MVG 1.3% or vehicle vaginal gel. Primary efficacy measure was clinical cure (normal discharge, negative “whiff test,” and <20% clue cells) at day 21. Secondary measures included therapeutic cure (both clinical and bacteriological; day 21) and bacteriologic cure (Nugent score <4), clinical cure, and time to resolution of symptoms (day 7). RESULTS: A total of 487 participants were included in the primary analysis. Clinical and therapeutic cure rates (day 21) were higher in participants treated with MVG 1.3% compared with vehicle gel (37.2% vs. 26.6% [P = 0.010] and 16.8% vs. 7.2% [P = 0.001], respectively). Clinical and bacteriologic cure rates (day 7) were also higher in the MVG 1.3% group (46.0% vs. 20.0% [P < 0.001] and 32.7% vs. 6.3% [P < 0.001], respectively). The median time to resolution of symptoms was shorter in the MVG 1.3% (day 6) than vehicle group (not reached). No serious adverse events were reported, and incidence was similar across treatment groups. CONCLUSIONS: Single-dose MVG 1.3% was safe and superior to vehicle gel in producing cure among women with BV. Lippincott Williams & Wilkins 2015-07 2015-06-11 /pmc/articles/PMC4463027/ /pubmed/26222750 http://dx.doi.org/10.1097/OLQ.0000000000000300 Text en Copyright © 2015 American Sexually Transmitted Diseases Association All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Original Study Schwebke, Jane R. Marrazzo, Jeanne Beelen, Andrew P. Sobel, Jack D. A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis |
title | A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis |
title_full | A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis |
title_fullStr | A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis |
title_full_unstemmed | A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis |
title_short | A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis |
title_sort | phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis |
topic | Original Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463027/ https://www.ncbi.nlm.nih.gov/pubmed/26222750 http://dx.doi.org/10.1097/OLQ.0000000000000300 |
work_keys_str_mv | AT schwebkejaner aphase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis AT marrazzojeanne aphase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis AT beelenandrewp aphase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis AT sobeljackd aphase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis AT schwebkejaner phase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis AT marrazzojeanne phase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis AT beelenandrewp phase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis AT sobeljackd phase3multicenterrandomizeddoubleblindvehiclecontrolledstudyevaluatingthesafetyandefficacyofmetronidazolevaginalgel13inthetreatmentofbacterialvaginosis |